AstraZeneca heads to 2018 ASCO Annual Meeting with its diversified oncology portfolio and next-generation pipeline
|
24 May 2018 |
AstraZeneca provides update on GALATHEA Phase III trial for Fasenra in chronic obstructive pulmonary disease
|
11 May 2018 |
AstraZeneca and Luye Pharma Group enter agreement for rights to Seroquel and Seroquel XR in the UK, China and other international markets
|
07 May 2018 |
Lokelma approved in the EU for the treatment of adults with hyperkalaemia
|
22 March 2018 |
New data from landmark CVD-REAL study of patients with type-2 diabetes confirms CV benefits associated with SGLT-2 Inhibitors
|
14 March 2018 |
MedImmune to create stand-alone company for early-stage inflammation and autoimmunity biologics
|
28 February 2018 |
Brilinta significantly reduces CV events and coronary death beyond one year in heart attack survivors with multi-vessel disease
|
07 February 2018 |
AstraZeneca listed as one of the world's top-100 most sustainable companies and recognised for its three-fold increase in renewable energy usage
|
23 January 2018 |
New research paper shows that AstraZeneca has achieved greater than four-fold improvement in R&D productivity
|
19 January 2018 |
US FDA accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer
|
18 December 2017 |